Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,133.85
    +54.99 (+0.68%)
     

  • Bitcoin USD

    64,635.99
    +956.40 (+1.50%)
     

  • CMC Crypto 200

    1,338.43
    -58.10 (-4.15%)
     

  • S&P 500

    5,104.62
    +56.20 (+1.11%)
     

  • Dow

    38,276.89
    +191.09 (+0.50%)
     

  • Nasdaq

    15,920.56
    +308.80 (+1.98%)
     

  • Gold

    2,354.70
    +12.20 (+0.52%)
     

  • Crude Oil

    84.01
    +0.44 (+0.53%)
     

  • 10-Yr Bond

    4.6510
    -0.0550 (-1.17%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Company News for Dec 1, 2021

Zacks Equity Research
·1-min read

  • Chico's FAS, Inc.’s CHS shares rose 3.2% after the company reported third-quarter 2021 earnings of 18 cents per share, beating the Zacks Consensus Estimate of a loss of 3 cents.

  • Shares of Citi Trends, Inc. CTRN jumped 8.4%after the company reported third-quarter 2021 earnings of $1.03 per share, beating the Zacks Consensus Estimate of 48 cents.

  • ImmunoGen, Inc.’s IMGN shares surged 29.9% after the company announced positive topline data from the SORAYA trial of mirvetuximab soravtansine for ovarian cancer.

  • Shares of ERYTECH Pharma S.A. ERYP jumped 13.6% after the company secured US patent directed to sequential use of methioninase & asparaginase against solid tumors.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Chico's FAS, Inc. (CHS) : Free Stock Analysis Report
 
Citi Trends, Inc. (CTRN) : Free Stock Analysis Report
 
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
 
Erytech Pharma SA Sponsored ADR (ERYP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research